top of page
  • Completed

NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1

Updated: Mar 28, 2022


Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore, clinical experience in advanced multiple myeloma (MM) patients treated by oral panobinostat and i.v bortezomib ± dexamethasone showed very encouraging results for efficacy and manageable toxicity profile.

Given the medical need for improved treatment strategies for patients with previously treated and relapsed MM, the purpose of this prospective, multinational, randomized, double-blind, placebo-controlled, parallel group Phase III study is to compare the results in progression-free survival of 2 combination therapies, panobinostat with bortezomib and dexamethasone or placebo with bortezomib and dexamethasone, in patients with previously treated MM whose disease has recurred or progressed.


Novartis Pharmaceuticals

International Study

Multiple Locations Identifier: NCT01023308



Drug: Panobinostat

Drug: Bortezomib

Drug: Dexamethasone

Drug: Placebo


Lancet Oncol; Oct. 2014

Adv Ther. 2016 Nov

Lancet Haematol. 2016 Nov

Blood. 2016 Feb


Não foi possível carregar comentários
Parece que houve um problema técnico. Tente reconectar ou atualizar a página.
Posts Archive
bottom of page